ArticleScientific reports2025
Co-administration of Spirulina and L-carnitine preserves ovarian reserve in a rat model of premature ovarian insufficiency via SIRT1 regulation of oxidative stress, inflammation, and apoptosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the possible consequences of spirulina (SP) and/or L-carnitine (L-car) on the prevention of primordial follicular reserve depletion and the preservation of ovarian follicular structure and function in a rat model of premature ovarian insufficiency (POI). Forty healthy adult female Sprague-Dawley albino rats were randomly assigned into five equal-sized groups (n = 8): normal control, DOX group (2.5 mg/kg i.p.), SP group (500 mg/kg intragastric), L-car group (250 mg/kg i.p.), and SP + L-car group in the same previous doses. In comparison to the DOX group, administration of either SP or L-car significantly increased serum E2 and AMH levels along with a significant decrease in the FSH and LH levels (p < 0.05). The oxidative stress was significantly reduced. Ovarian expressions of NF-κB, iNOS, FOXO1, P53, and caspase-3 decreased significantly, while SIRT1, STAR, CYP17A1, HSD17B3, Nrf2, and mtDNA increased significantly. Histology revealed histoarchitecture improvement as the mean % of atretic follicles and degenerated corpora lutea was significantly reduced (p < 0.05). The combined treatments synergistically improved the parameters studied more than either treatment alone. The molecular docking results revealed the ability of both n-hexadecanoic acid and L-carnitine to activate SIRT1 and subsequent antioxidant, anti-inflammatory, and anti-apoptotic pathways. This ovoprotective effect is suggested to be mediated through activation of different SIRT1-mediated protective signaling pathways that remodel ovarian redox status, inflammation, and apoptosis, which may strengthen the potential role of SP and L-car as a chemotherapy adjuvant, reducing the negative health effects of early menopause after cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.